Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Legal and Privacy Notices

    ... General Disclaimer The Aplastic Anemia and MDS International Foundation (AAMDSIF) created and maintains this Web site as a ... offered by the AAMDSIF. Users may opt out of any such secondary use of personal information by calling the AAMDSIF at (800) 747-2820. ...

    Page last updated 11/01/2016 - 11:24am.

  2. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... PubMed Abstract:  Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease ... are found in approximately 50% of primary MDS and 80% of secondary MDS , which develops in the setting of prior chemotherapy ...

    Research Review last updated 05/02/2016 - 9:14am.

  3. Causes

    ... De Novo MDS The cause of most MDS cases is ... doctors call this: Therapy-related MDS Secondary MDS On average, treatment-related MDS happens 5 to 7 years ...

    Topic section last updated 03/10/2016 - 10:59pm.

  4. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... AML arising from MDS or a myeloproliferative disorder, or secondary AML Presence of Flt3 internal tandem duplications Poor-risk ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  5. Bone Marrow Transplant

    ... doctor about bone marrow transplant options. MDS : Whether patients with MDS should undergo hematopoietic stem cell transplantation (HSCT) as soon as ... can also affect SCT outcomes. People with secondary MDS , caused by a previous treatment for another disease or ...

    Topic section last updated 03/29/2016 - 7:27pm.

  6. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... CD123+ acute myeloid leukemia (AML) de novo , or secondary Relapsed AML is defined as patients that had a first complete ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  7. Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

    ... to patients with relapsed and/or refractory AML, MDS, or ALL. Status:  ... PHASE I -- a. Primary or secondary AML according to WHO classification, with relapsed or refractory ...

    Clinical Trial last updated 06/06/2016 - 10:59am.

  8. Myelofibrosis (MF)

    ... vera or essential thrombocytosis. This is called secondary myelofibrosis. Patients with MDS, leukemia or even lymphoma can also have fibrosis in their bone ...

    Topic section last updated 07/07/2016 - 3:16pm.

  9. Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)

    ... a UCB transplant can improve response in participants with MDS, leukemia, lymphoma, or MM. The safety of this treatment and whether NK ... of minimal residual disease by flow cytometry ), secondary leukemia from prior chemotherapy and/or arising from MDS, any ...

    Clinical Trial last updated 06/06/2016 - 10:28am.

  10. Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... of minimal residual disease by flow cytometry ), secondary leukemia from prior chemotherapy and/or arising from MDS, ...

    Clinical Trial last updated 06/06/2016 - 12:58pm.